Neonatal infections due to multi-resistant strains: Epidemiology, current treatment, emerging therapeutic approaches and prevention

Clinica Chimica Acta; International Journal of Clinical Chemistry
Chryssoula TziallaMauro Stronati

Abstract

Severe infections represent the main cause of neonatal mortality accounting for more than one million neonatal deaths worldwide every year. Antibiotics are the most commonly prescribed medications in neonatal intensive care units. The benefits of antibiotic therapy when indicated are clearly enormous, but the continued and widespread use of antibiotics has generated over the years a strong selective pressure on microorganisms, favoring the emergence of resistant strains. Health agencies worldwide are galvanizing attention toward antibiotic resistance in gram-positive and gram-negative bacteria. Infections in neonatal units due to multidrug and extensively multidrug resistant bacteria are rising and are already seriously challenging antibiotic treatment options. While there is a growing choice of agents against multi-resistant gram-positive bacteria, new options for multi-resistant gram-negative bacteria in the clinical practice have decreased significantly in the last 20 years making the treatment of infections caused by multidrug-resistant pathogens challenging mostly in neonates. Treatment options are currently limited and will be some years before any new treatment for neonates become available for clinical use, if ever. The...Continue Reading

References

Apr 18, 2000·Lancet·P de ManJ N van den Anker
Nov 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Helen W BoucherJohn Bartlett
Dec 17, 2009·American Journal of Perinatology·Kosmas SarafidisEmmanuel Roilides
Apr 28, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alison J CareyLisa Saiman
Jun 30, 2010·Archives of Disease in Childhood. Fetal and Neonatal Edition·B Muller-PebodyUNKNOWN iCAP Group (Improving Antibiotic Prescribing in Primary Care)
Sep 30, 2010·Archives of Disease in Childhood. Fetal and Neonatal Edition·Stefania VergnanoPaul T Heath
Nov 3, 2010·Archives of Disease in Childhood. Fetal and Neonatal Edition·Alison Bedford RussellPaul T Heath
Feb 15, 2011·The Pediatric Infectious Disease Journal·Sarita J DepaniMike Sharland
May 19, 2011·Archives of Disease in Childhood. Education and Practice Edition·James William Gray, Mitul Patel
Jan 25, 2012·Infection·C AntachopoulosE Roilides
Feb 22, 2012·Clinics in Perinatology·Nidhi TripathiP Brian Smith
Mar 15, 2012·The Journal of Antimicrobial Chemotherapy·Martin E StryjewskiG Ralph Corey
Mar 28, 2012·Pediatrics·Richard A PolinUNKNOWN Committee on Infectious Diseases
Jun 6, 2012·Archives of Pediatrics & Adolescent Medicine·Megan A Moreno
Nov 21, 2012·Seminars in Fetal & Neonatal Medicine·M MussapV Fanos
Nov 28, 2012·Seminars in Perinatology·Melissa U Nelson, Patrick G Gallagher
Nov 28, 2012·Seminars in Perinatology·Sameer J Patel, Lisa Saiman
Jan 25, 2013·The New England Journal of Medicine·Brad SpellbergDavid N Gilbert
Jan 30, 2013·Diagnostic Microbiology and Infectious Disease·Gary E Stein, Timothy Babinchak
Feb 5, 2013·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·B D Schoub
Feb 16, 2013·Antimicrobial Resistance and Infection Control·Anna-Pelagia MagiorakosUNKNOWN EARS-Net Coordination Group and EARS-Net participants
Mar 8, 2013·International Journal of Antimicrobial Agents·David J FarrellRonald N Jones
May 1, 2013·Nature Reviews. Drug Discovery·Kim Lewis
May 15, 2013·American Journal of Infection Control·Elias IosifidisEmmanuel Roilides
Oct 5, 2013·Journal of Chemotherapy·Gian Maria Pacifici, Karel Allegaert
Dec 19, 2013·The Pediatric Infectious Disease Journal·Adem KarbuzErdal İnce
Jan 21, 2014·Expert Opinion on Pharmacotherapy·Stuart L Burke, Warren E Rose
Feb 7, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alice J Hsu, Pranita D Tamma
Feb 19, 2014·Current Infectious Disease Reports·James W GrayPhilip Milner
Apr 9, 2014·Early Human Development·Angelica DessìVassilios Fanos
Apr 9, 2014·Early Human Development·Thomas A Hooven, Richard A Polin
Apr 17, 2014·JAMA : the Journal of the American Medical Association·Bridget M Kuehn
Apr 29, 2014·Expert Opinion on Pharmacotherapy·Ilias Karaiskos, Helen Giamarellou
May 3, 2014·Nature·Megan Cully
Aug 26, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Brad Spellberg, David N Gilbert

❮ Previous
Next ❯

Citations

Oct 28, 2017·Archives of Disease in Childhood. Fetal and Neonatal Edition·Benjamin CailesUNKNOWN neonIN network
Jan 25, 2019·Journal of Chemotherapy·Almudena Alonso-OjembarrenaSimón Pedro Lubián-López
Oct 29, 2015·Journal of Perinatology : Official Journal of the California Perinatal Association·L A DenkelB Piening
Feb 18, 2016·Current Opinion in Pediatrics·Charles M Cotten

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Related Papers

Italian Journal of Pediatrics
Chryssoula TziallaGiovanni Corsello
Zentralblatt für Chirurgie
S HagelM Pletz
Expert Review of Anti-infective Therapy
Carlota Gudiol, Jordi Carratalà
© 2022 Meta ULC. All rights reserved